{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T10:14:44Z","timestamp":1783332884159,"version":"3.54.6"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the relationship between serum biomarkers [vascular endothelial growth factor (VEGF), matrix metalloproteinase-3, and leptin] and disease activity, and the changes in those biomarker levels during tumour necrosis factor inhibitor (TNFi) treatment in patients with axial spondyloarthritis (axSpA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with axSpA initiating their first TNFi who had serum samples at baseline and the sixth month of therapy were included, and the relationship between these biomarkers and disease activity, and functional parameters was analysed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 74 axSpA patients [mean age (SD) 48.7 (12.8) years, 54.1% male] were included. Disease activity parameters (Bath Ankylosing Spondylitis Disease Activity Index, Ankylosing Spondylitis Disease Activity Score-based C-reactive protein, and Bath Ankylosing Spondylitis Disease Functional Index) and C-reactive protein were significantly decreased at the sixth month of TNFi therapy (all P\u2009&amp;lt;\u2009.001). The correlation between biomarker levels and disease activity was evaluated, and only serum matrix metalloproteinase-3 levels were found to be associated with baseline Ankylosing Spondylitis Disease Activity Score-based C-reactive protein (P\u2009=\u2009.02). Serum VEGF levels decreased compared to the baseline at the sixth month (P\u2009&amp;lt;\u2009.001), however, serum leptin and matrix metalloproteinase-3 levels were not affected by TNFi (P\u2009=\u2009.50). Serum VEGF levels were substantially correlated with gender, hip involvement, delay in diagnosis, and disease activity in the longitudinal analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients with axSpA, TNFi therapy significantly reduces serum VEGF levels and effectively reduces disease activity. VEGF has the potential to function as a dynamic biomarker that reflects the characteristics of the disease and the response to treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/mr\/roag004","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T12:38:48Z","timestamp":1771072728000},"page":"635-640","source":"Crossref","is-referenced-by-count":0,"title":["Serum VEGF levels may have a role in the assessment of treatment response and disease activity during TNFi therapy in patients with axSpA"],"prefix":"10.1093","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3116-1133","authenticated-orcid":false,"given":"Merve G\u00fcle\u00e7","family":"Yaz\u0131r","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Izmir Katip Celebi University , Izmir ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif Durak","family":"Edibo\u011flu","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Izmir Katip Celebi University , Izmir ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K\u00fcbra","family":"Kaya","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Medicine, Y\u0131ld\u0131r\u0131m Beyazit University , Ankara ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6khan","family":"Kabaday\u0131","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Izmir Katip Celebi University , Izmir ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyla Didem","family":"Kozac\u0131","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Medicine, Y\u0131ld\u0131r\u0131m Beyazit University , Ankara ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilek","family":"Solmaz","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Izmir Katip Celebi University , Izmir ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"\u00d6zmen","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Izmir Katip Celebi University , Izmir ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Servet","family":"Akar","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Izmir Katip Celebi University , Izmir ,","place":["T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,14]]},"reference":[{"key":"2026070605222541900_ref1","doi-asserted-by":"publisher","first-page":"ii1","DOI":"10.1136\/ard.2008.104018","article-title":"The assessment of spondyloarthritis international society (ASAS) handbook: A guide to assess spondyloarthritis","volume":"68","author":"Sieper","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2026070605222541900_ref2","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1046\/j.1365-2249.2003.02101.x","article-title":"High serum vascular endothelial growth factor correlates with disease activity of spondylarthropathies","volume":"132","author":"Drouart","year":"2003","journal-title":"Clin Exp Immunol"},{"key":"2026070605222541900_ref3","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1136\/annrheumdis-2013-203824","article-title":"Elevated serum level of the vascular endothelial growth factor predicts radiographic spinal progression in patients with axial spondyloarthritis","volume":"73","author":"Poddubnyy","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2026070605222541900_ref4","first-page":"357","article-title":"The serum matrix metalloproteinase-1, 3, 9 level in patients with ankylosing spondylitis and its significance","volume":"23","author":"Lin","year":"2008","journal-title":"Lab Med"},{"key":"2026070605222541900_ref5","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1158\/1078-0432.CCR-06-2416","article-title":"Vascular endothelial growth factor and its relationship to inflammatory mediators","volume":"13","author":"Angelo","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2026070605222541900_ref6","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1136\/ard.2007.071605","article-title":"Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab","volume":"67","author":"Visvanathan","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"2026070605222541900_ref7","doi-asserted-by":"crossref","first-page":"1759720X211030809","DOI":"10.1177\/1759720X211030809","article-title":"Factors associated with risk of major adverse cardiovascular events in patients with rheumatoid arthritis: A nationwide, population-based, case-control study","volume":"13","author":"Chen","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2026070605222541900_ref8","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.3899\/jrheum.101128","article-title":"Serum MMP-3 level as a biomarker for monitoring and predicting response to etanercept treatment in ankylosing spondylitis","volume":"38","author":"Arends","year":"2011","journal-title":"J Rheumatol"},{"key":"2026070605222541900_ref9","doi-asserted-by":"publisher","first-page":"565","DOI":"10.55563\/clinexprheumatol\/ou570o","article-title":"Serum leptin concentration is associated with the attainment of clinical outcomes in patients with axial spondyloarthritis treated with TNF inhibitors","volume":"41","author":"Hern\u00e1ndez-Breijo","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"2026070605222541900_ref10","first-page":"538","article-title":"Leptin and visfatin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-\u03b1 antagonist therapy","volume":"31","author":"Miranda-Filloy","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"2026070605222541900_ref11","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part II): Validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2026070605222541900_ref12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2026070605222541900_ref13","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1136\/ard-2022-223296","article-title":"Serum levels of matrix metalloproteinase 3 and macrophage colony-stimulating factor 1 correlate with disease activity in ankylosing spondylitis","volume":"51","author":"Yang","year":"2004","journal-title":"Arthritis Care Res Off J Am Coll Rheumatol"},{"key":"2026070605222541900_ref14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar3857","article-title":"Association of cytokine and matrix metalloproteinase profiles with disease activity and function in ankylosing spondylitis","volume":"14","author":"Mattey","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"2026070605222541900_ref15","first-page":"880","article-title":"Leptin and adiponectin levels in patients with ankylosing spondylitis. The effect of infliximab treatment","volume":"28","author":"Derdemezis","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"2026070605222541900_ref16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nm0195-27","article-title":"Angiogenesis in cancer, vascular, rheumatoid and other disease","volume":"1","author":"Folkman","year":"1995","journal-title":"Nat Med"},{"key":"2026070605222541900_ref17","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1046\/j.1365-2613.1999.00129.x","article-title":"New vessels, new approaches: Angiogenesis as a therapeutic target in musculoskeletal disorders","volume":"80","author":"Ballara","year":"1999","journal-title":"Int J Exp Pathol"},{"key":"2026070605222541900_ref18","first-page":"17","article-title":"Vascular endothelial growth factor: A key mediator of neoangiogenesis. A review","volume":"1","author":"Amoroso","year":"1997","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2026070605222541900_ref19","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.3899\/jrheum.101128","article-title":"Serum MMP-3 level as a biomarker for monitoring and predicting response to etanercept treatment in ankylosing spondylitis","volume":"38","author":"Arends","year":"2011","journal-title":"J Rheumatol"},{"key":"2026070605222541900_ref20","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1093\/rheumatology\/kez025","article-title":"Added value of biomarkers compared with clinical parameters for the prediction of radiographic spinal progression in axial spondyloarthritis","volume":"58","author":"Rademacher","year":"2019","journal-title":"Rheumatology"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roag004\/66901528\/roag004.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/4\/635\/66901528\/roag004.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/4\/635\/66901528\/roag004.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T09:23:13Z","timestamp":1783329793000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/36\/4\/635\/8483858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,14]]},"references-count":20,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,2,14]]},"published-print":{"date-parts":[[2026,6,30]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roag004","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,2,14]]}}}